We pride ourselves on our deep domain knowledge in healthcare, and subsector specialization across biopharma, medical technology, life sciences and healthcare services.
Our senior investment team has on average 20+ years of experience investing in the healthcare sector, and has fostered a valuable relationship network across the public and private corporate universe, KOLs, doctors, regulatory and legal experts, venture capital, industry specialists, consultants, sell-side research and investment banking.
Our culture is rooted in creativity, collaboration and an entrepreneurial spirit.
At PFM Health Sciences, we pride ourselves on fostering a meritocratic culture based on collaboration, transparency and integrity. Our team is a diverse group of individuals with decades of investment and industry experience who are tied together by intellectual curiosity, a willingness to adapt and a drive to succeed.
Our aim is to provide our team with a dynamic and entrepreneurial platform for growth.
Senior Investment Team
Brian Grossman
Brian Grossman
Brian started his career in 1996 as a convertible bond analyst at J.P. Morgan Investment Management (JPMIM). In 1998, he became an equity research analyst covering medtech, healthcare services and ultimately biotech. Following time at Pequot Capital and Andor Capitol, Brian was a founding partner of Partner Fund Management (PFM) in 2004. Soon after establishing PFM, the Diversified strategy (November 2004) and dedicated Healthcare strategy (December 2005) were launched. Brian was the co-portfolio manager for the Diversified strategy and the sole portfolio manager for the Healthcare strategy. In 2020, Brian became PFM’s sole managing partner, and the firm changed its name to PFM Health Sciences. Brian is a graduate of The University of Pennsylvania with a B.S. in Economics and is a CFA® charterholder. Brian is a member of the USCF Board of Observers and co-chair of the UCSF Health Executive Council.
Anant Ahuja
Anant Ahuja
Prior to joining PFM in 2014, Anant was an Analyst for the Global Equities Fund at Omers Capital Markets (2011-2014). Before Omers, he was a Consulting Healthcare Analyst at Spencer Capital Management (2010-2011). Prior to Spencer Capital, Anant was an Analyst with Opus Point Partners (2008-2009) and a Resident Physician at Albert Einstein College of Medicine (2005-2008). Anant graduated from North Carolina State University with a B.S. in Zoology, received his M.D. from New York Medical College and received his MBA from Columbia Business School.
David Shaw
David Shaw
Prior to rejoining PFM, David was a Portfolio Manager at Balyasny Asset Management where he focused on Biopharma (2016-2021). From 2014-2016 he was a Seed and Early-Stage Investor at SummitVision Capital. Prior to this, he was a Senior Investment Analyst at Citadel (2011-2013). From 2009-2011, David was an Analyst covering Biopharma for PFM. Prior to PFM, he was an Analyst at J. Goldman & Co. (2006-2008), JPMorgan Chase & Co. (2004-2006), First Albany Capital (2003-2004), Wachovia Securities (2002-2003) and Robertson Stephens (2000-2002). David graduated from Colgate University with a B.A. in Molecular Biology and is a CFA® Charterholder.
Santhosh Palani
Santhosh Palani
Prior to joining PFM in 2020, Santhosh was a Principal at New Enterprise Associates (NEA) where he invested in early stage private companies in the Biopharma sector and served on the boards of companies in the cell therapy, targeted oncology, radiopharmaceuticals and gene editing fields. From 2016-2018 Santhosh was a Vice President at Cowen and Company in Equity Research, where he covered SMID Cap Biotech stocks across numerous therapeutic areas. He previously served as an Associate Director in Oncology Clinical Development at Pfizer (2013-2016) and as a Scientist in Oncology Preclinical Development at Takeda Pharmaceuticals (2012-2013). Santhosh graduated with a B.S. and M.S. in Chemical Engineering from the University of Madras and Texas A&M University, respectively. Santhosh earned his PhD in Bioengineering from the University of Pennsylvania and completed his postdoctoral work in Biochemistry and Molecular Biophysics at Columbia University. Santhosh is a CFA® Charterholder.
Vivek Khanna
Vivek Khanna
Prior to joining PFM in 2012, Vivek was an Analyst at Catapult Partners/Millennium LLP (2011-2012). Before Millennium, he was an Analyst/Sector Head at Argus/Sivik Healthcare (2002-2011). Prior to Sivik Healthcare, Vivek was an Executive Director of Equity Research with UBS Investment Bank (1999-2002), Vice President of Equity Research with Smith Barney (1993-1996) and an Analyst at Blue Cross Blue Shield of National Capital Area (1991-1993). Vivek is a graduate of Delhi University with a B.A. in Economics and received his MBA from the College of William and Mary.
Management Team
Christopher Mosellen
Christopher Mosellen
Prior to joining PFM in 2007, Chris was a Principal and Portfolio Manager/Trader focusing on credit trading strategies with Barclays Global Investors (2003-2007). Before BGI, he was an Associate Vice President at Standish Mellon Asset Management (2001-2003). Chris graduated from Bentley College with a B.S. in Economics-Finance and is a CFA® charterholder.
Darren Mooney
Darren Mooney
Prior to rejoining PFM in 2023, Darren was a Senior Managing Director in IQ-EQ’s Regulatory Compliance practice group, following IQ-EQ’s 2021 acquisition of Greyline Partners, where he was Partner. Prior to serving as Deputy Chief Compliance Officer at PFM (2019-2020), he was a Senior Principal Consultant at ACA Compliance Group following its 2018 acquisition of Cordium (2015-2019). Before ACA, he worked as the Deputy Chief Compliance Officer for F-Squared Investments in Massachusetts (2013-2015). He started his career as a Business Services/Financial Analyst for J.P. Morgan (2008-2010). Darren graduated with a B.S. in Business Administration and Economics from the University of Delaware and received his JD from Suffolk University Law School. Darren is admitted to the State Bar of Massachusetts.
Graham Low
Graham Low
Prior to joining PFM in 2007, Graham was a Managing Director in U.S. Equity Sales at Merrill Lynch (1997-2007). Before business school, he was a Private Wealth Advisor with Merrill Lynch (1992-1995). Graham is a graduate of the University of New Mexico with a degree in Marketing/Business Administration and received his MBA from UCLA’s Anderson School of Management.
Jonathan Aljoe
Jonathan Aljoe
Prior to joining PFM in 2014, Jonathan was a Tax Manager in the Financial Services Group at Burr Pilger Mayer LLP (2008-2014). He was the Co-Founder and Chief Financial Officer at Cerbae LLC from 2005-2008. Before Cerbae, Jonathan was a Senior Tax Associate at Gaytan Kallman and Company LLP (2003-2005). Jonathan is a graduate of the University of California, Los Angeles with a B.A. in Economics.